Angelini Pharma Agrees to Acquire Catalyst Pharma for up to $4.1B

Why It Matters

The transaction gives Angelini a foothold in the lucrative U.S. rare‑disease market and secures a high‑margin, patent‑protected product, accelerating its ambition to compete globally. It also boosts Angelini’s revenue base, positioning the group for stronger growth and scale.

Key Takeaways

• Angelini pays $31.50 per share, 28% premium to Catalyst price.
• Deal adds three FDA‑approved neuromuscular/epilepsy drugs worth $589M last year.
• Catalyst's flagship Firdapse generated $358M, patent protected until 2035.
• Angelini's revenue jumps from $1.9B to over $2.5B post‑acquisition.
• First Angelini US acquisition since 2021, signaling global expansion.

Pulse Analysis

Angelini Pharma, a family‑owned Italian group with a century‑long legacy, has long pursued a transformation toward a global specialty‑medicine champion. The $4.1 billion acquisition of Nasdaq‑listed Catalyst Pharma marks the company’s first direct foothold in the United States, a market that accounts for roughly 40 % of worldwide pharmaceutical revenues. By offering a 28 % premium of $31.50 per share, Angelini signals both financial muscle and strategic urgency. The deal follows a 2021 purchase of Swiss CNS specialist Arvelle Therapeutics, underscoring a five‑year plan to scale in neurology and rare diseases.

Catalyst brings three FDA‑approved products into Angelini’s pipeline: Firdapse for Lambert‑Eaton myasthenic syndrome, Agamree for Duchenne muscular dystrophy, and Fycompa for epilepsy. Together they generated $589 million in 2023 sales and are projected to reach $645 million by 2026, with Firdapse alone contributing $358 million. The acquisition coincides with Catalyst’s settlement of a patent dispute with India’s Hetero Labs, preserving Firdapse’s exclusivity until 2035. While Fycompa now faces generic erosion, the growth of Agamree—up 154 % to $117 million—offers a promising rare‑disease revenue stream.

The transaction reflects a broader wave of consolidation in the rare‑neurological space, where scale and protected IP are critical to offset high R&D costs. For Angelini, the added U.S. sales platform and established distribution network accelerate its ambition to compete with larger multinational players such as Roche and Novartis. Investors are likely to view the deal as a catalyst for earnings expansion, given the projected revenue lift from $1.9 billion to well over $2.5 billion. Success will hinge on integrating Catalyst’s commercial operations and leveraging the extended patent life of its flagship drug.

Deal Summary

Italy's Angelini Pharma announced it will acquire US‑listed Catalyst Pharma for up to $4.1 billion, paying $31.50 per share (a 28% premium). The acquisition gives Angelini three FDA‑approved neuromuscular and epilepsy products and marks its entry into the US market. The deal was disclosed on May 7, 2026.